<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9475">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05697016</url>
  </required_header>
  <id_info>
    <org_study_id>HX-B-2022083</org_study_id>
    <nct_id>NCT05697016</nct_id>
  </id_info>
  <brief_title>Sivelestat for Acute Respiratory Distress Syndrome Due to COVID-19</brief_title>
  <official_title>Sivelestat for the Treatment of Adult Patients With Acute Respiratory Distress Syndrome Due to COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-Blind, placebo-controlled trial aimed to investigate the safety and&#xD;
      efficacy of sivelestat on treating adult patients with COVID-19-related acute respiratory&#xD;
      distress syndrome (ARDS)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a randomized, double-blind, placebo-controlled clinical trial, and&#xD;
      is planned to be conducted at 3 clinical centers in China from January 1, 2023, to January&#xD;
      31, 2024. During the study period, we intend to enroll a total of 238 eligible patients.&#xD;
      These patients will be randomly assigned in a 1:1 ratio to receive either sivelestat sodium&#xD;
      or placebo via continuous intravenous infusion (0.2mg/kg/h) over a 24-hour period for 7 days&#xD;
      (or to the day of death or ICU discharge if it occurs before day 7). Both the patients and&#xD;
      investigators are blinded to the treatment assignment. Subsequent follow-ups will be&#xD;
      performed in person at 7,14 and 28 days after randomization. The primary endpoint will be at&#xD;
      7 days post randomization and secondary endpoints will be at 14 and 28 days post&#xD;
      randomization. Also, endpoint assessors are masked to the treatment allocation. Lastly, these&#xD;
      endpoint variables will be compared between the treatment groups to investigate the efficacy&#xD;
      and safety of sivelestat for COVID-19-associated ARDS&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2023</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 3, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>From randomization to day 7</time_frame>
    <description>Changes in the PaO2/FiO2 ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator-Free days</measure>
    <time_frame>From randomization to day 28</time_frame>
    <description>The number of Ventilator-Free Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Through study completion, a period of 28 days</time_frame>
    <description>The rate of death during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>Through study completion, a period of 28 days</time_frame>
    <description>The overall length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit (ICU) length of stay</measure>
    <time_frame>Through study completion, a period of 28 days</time_frame>
    <description>The time interval between ICU admission and ICU discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Respiratory Infection Virus</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>the Sivelestat group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in this group will receive sivelestat sodium via continuous intravenous infusion (0.2mg/kg/h) over a 24-hour period for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients in this group will receive the placebo via continuous intravenous infusion (0.2mg/kg/h) over a 24-hour period for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sivelestat Sodium for Injection</intervention_name>
    <description>Sivelestat, a specific inhibitor of neutrophil elastase; sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenyl-sulfonylaminobenzoyl]amino-acetate tetrahydrate]</description>
    <arm_group_label>the Sivelestat group</arm_group_label>
    <other_name>Supportive management of ARDS (e.g., protective ventilation strategy, prone positioning and/or VV-ECMO, etc.) based on currently recommended practice guidelines</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The Placebo</intervention_name>
    <description>Excipients used for the sivelestat sodium</description>
    <arm_group_label>The Placebo group</arm_group_label>
    <other_name>Supportive management of ARDS (e.g., protective ventilation strategy, prone positioning and/or VV-ECMO, etc.) based on currently recommended practice guidelines</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years old&#xD;
&#xD;
          -  Confirmed SARS-CoV-2 infection as determined by Polymerase Chain Reaction (PCR) in&#xD;
             sputum, nasopharyngeal swabs, or oropharyngeal swabs&#xD;
&#xD;
          -  Diagnosis of acute respiratory distress syndrome (ARDS) according to the Berlin&#xD;
             Definition criteria&#xD;
&#xD;
          -  Onset of ARDS less than 72 hours before randomization&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ARDS potentially caused by extra-pulmonary reasons, including non-pulmonary sepsis,&#xD;
             pancreatitis, multiple trauma and massive transfusion, etc.&#xD;
&#xD;
          -  Leukopenia (leukocyte count &lt;4,000/μL/) and/or thrombocytopenia (platelet count&#xD;
             &lt;100,000/μL)&#xD;
&#xD;
          -  Significant hepatic dysfunction, defined as elevated AST and ALT ≥ 3 times the normal&#xD;
             limits, or total bilirubin ≥ 1.5 mg/dL&#xD;
&#xD;
          -  Severe renal insufficiency with serum creatinine &gt; 3.0 mg/dL&#xD;
&#xD;
          -  History of moderate to severe chronic lung disease requiring home-based oxygen&#xD;
             therapy, including chronic obstructive pulmonary disease (COPD), interstitial lung&#xD;
             disease (ILD), asthma and bronchiectasis, etc.&#xD;
&#xD;
          -  Pre-existing peripheral nerve injury, spinal cord trauma, or neuromuscular disorder&#xD;
             that may impair spontaneous ventilation (e.g., high cervical spinal cord injury,&#xD;
             Guillain-Barré Syndrome, and myasthenia gravis, etc.)&#xD;
&#xD;
          -  Current diagnosis of pulmonary embolism&#xD;
&#xD;
          -  Coexisting multi-organ failure, affecting more than 3 systems&#xD;
&#xD;
          -  Combined with burn injury&#xD;
&#xD;
          -  Life expectancy less than 6 months (e.g., due to an an end-stage malignant disease)&#xD;
&#xD;
          -  Moribund and expected to die within 48 hours&#xD;
&#xD;
          -  Known allergy to sivelestat or any of the study drug excipients&#xD;
&#xD;
          -  Pregnancy or lactation, or the possibility of conception&#xD;
&#xD;
          -  Current or recent (last 3 months) participation in any other clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guangzhi Shi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhigang Zhao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingwei Zhao, M.D.</last_name>
    <phone>86-010-59975098</phone>
    <email>126-zjw@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bin Zhu, M.D.</last_name>
    <phone>86-010-59975442</phone>
    <email>zbtcm@163.com</email>
  </overall_contact_backup>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 16, 2023</study_first_submitted>
  <study_first_submitted_qc>January 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2023</study_first_posted>
  <last_update_submitted>January 22, 2023</last_update_submitted>
  <last_update_submitted_qc>January 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Guangzhi Shi</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Sivelestat</keyword>
  <keyword>Randomized Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sivelestat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

